Jump to content

GJA1: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Line 42: Line 42:
== Clinical significance ==
== Clinical significance ==


Overall, [[connexins]] are widely distributed [[proteins]] in the body that are specifically important for functions in the heart and the brain.<ref>{{cite journal|last1=Schulz|first1=R|last2=Görge|first2=PM|last3=Görbe|first3=A|last4=Ferdinandy|first4=P|last5=Lampe|first5=PD|last6=Leybaert|first6=L|title=Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.|journal=Pharmacology & therapeutics|date=September 2015|volume=153|pages=90-106|pmid=26073311}}</ref> <ref>{{cite journal|last1=Severs|first1=NJ|last2=Bruce|first2=AF|last3=Dupont|first3=E|last4=Rothery|first4=S|title=Remodelling of gap junctions and connexin expression in diseased myocardium.|journal=Cardiovascular research|date=1 October 2008|volume=80|issue=1|pages=9-19|pmid=18519446}}</ref><ref>{{cite journal|last1=Kelly|first1=JJ|last2=Simek|first2=J|last3=Laird|first3=DW|title=Mechanisms linking connexin mutations to human diseases.|journal=Cell and tissue research|date=June 2015|volume=360|issue=3|pages=701-21|pmid=25398718}}</ref> Six connexin subunits form a [[connexon]] or hemichannel in the plasma membrane. Interactions between two hemichannels in a head-to-head arrangement result in the formation of a [[gap junction]] channel. Hence, Gap junctions are necessary to coordinate cell function by passing electrical current flow between heart and nerve cells or by allowing exchange of chemical signals and energy substrates. In general, mutations of connexin proteins may lead to [[congenital]] diseases; the most frequent one is hearing loss. Moreover, in the heart, [[atrial fibrillation]] may result from mutations in [[connexin 40]]. However, connection proteins also play significant roles in acquired diseases. For instance, under pathological conditions, gap junctions may expand cell injury/cell death to surrounding healthy cells causing bystander effects, or "spreading" injury. Conversely, gap junctions may also act in a protective manner by supplying essential nutrients and metabolites, thereby preventing injury or death of healthy neighboring cells. Notably, in cardiac [[ischemia-reperfusion injury]] and myocardial [[infarction]] a decrease in gap junctional communications as a result of [[acidosis]], increased calcium concentration and altered [[phosphorylation]] and [[nitrosylation]] levels. Consequently, along with other alteration in other ion channels leads to an increased risk for [[arrhythmia]]. Furthermore, in brain ischemia, [[astrocytic]] gap junctional coupling decreases, and like in the heart, closure is incomplete. Decreased coupling hampers the spatial buffering of potassium and glutamate, and limits sharing of energy substrates from the astrocytic [[syncytium]] to neurons. The remaining coupling may be sufficient to propagate bystander injury and cell death between astrocytes and between gap junction-coupled neurons. Apart from Cx43, the special conduction system in the ventricles contains [[Cx45]]. In the atrioventricular and [[sinoatrial node]] of mice, Cx30.2 is expressed while its orthologous protein Cx31.9 is not detectable in the human cardiac conduction system.<ref>{{cite journal|last1=Severs|first1=NJ|last2=Bruce|first2=AF|last3=Dupont|first3=E|last4=Rothery|first4=S|title=Remodelling of gap junctions and connexin expression in diseased myocardium.|journal=Cardiovascular research|date=1 October 2008|volume=80|issue=1|pages=9-19|pmid=18519446}}</ref> The most abundant Cx in the brain and heart is Cx43. In the brain, Cx43 is most prominently expressed in astrocytes but is also present in microglial cells. In the heart, Cx43 is most prominently expressed in cardiomyocytes of the ventricles, but is also present in [[atrial cells]] and [[endothelial cells]].
Overall, [[connexins]] are widely distributed [[proteins]] in the body that are specifically important for functions in the heart and the brain.<ref>{{cite journal|last1=Schulz|first1=R|last2=Görge|first2=PM|last3=Görbe|first3=A|last4=Ferdinandy|first4=P|last5=Lampe|first5=PD|last6=Leybaert|first6=L|title=Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.|journal=Pharmacology & therapeutics|date=September 2015|volume=153|pages=90-106|pmid=26073311}}</ref> <ref>{{cite journal|last1=Severs|first1=NJ|last2=Bruce|first2=AF|last3=Dupont|first3=E|last4=Rothery|first4=S|title=Remodelling of gap junctions and connexin expression in diseased myocardium.|journal=Cardiovascular research|date=1 October 2008|volume=80|issue=1|pages=9-19|pmid=18519446}}</ref><ref>{{cite journal|last1=Kelly|first1=JJ|last2=Simek|first2=J|last3=Laird|first3=DW|title=Mechanisms linking connexin mutations to human diseases.|journal=Cell and tissue research|date=June 2015|volume=360|issue=3|pages=701-21|pmid=25398718}}</ref> Six connexin subunits form a [[connexon]] or hemichannel in the plasma membrane. Interactions between two hemichannels in a head-to-head arrangement result in the formation of a [[gap junction]] channel. Hence, Gap junctions are necessary to coordinate cell function by passing electrical current flow between heart and nerve cells or by allowing exchange of chemical signals and energy substrates. In general, mutations of connexin proteins may lead to [[congenital]] diseases; the most frequent one is hearing loss. Moreover, in the heart, [[atrial fibrillation]] may result from mutations in [[connexin 40]]. However, connection proteins also play significant roles in acquired diseases. For instance, under pathological conditions, gap junctions may expand cell injury/cell death to surrounding healthy cells causing bystander effects, or "spreading" injury. Conversely, gap junctions may also act in a protective manner by supplying essential nutrients and metabolites, thereby preventing injury or death of healthy neighboring cells. Notably, in cardiac [[ischemia-reperfusion]] injury and myocardial [[infarction]] a decrease in gap junctional communications as a result of [[acidosis]], increased calcium concentration and altered [[phosphorylation]] and [[nitrosylation]] levels. Consequently, along with other alteration in other ion channels leads to an increased risk for [[arrhythmia]]. Furthermore, in brain ischemia, [[astrocytic]] gap junctional coupling decreases, and like in the heart, closure is incomplete. Decreased coupling hampers the spatial buffering of potassium and glutamate, and limits sharing of energy substrates from the astrocytic [[syncytium]] to neurons. The remaining coupling may be sufficient to propagate bystander injury and cell death between astrocytes and between gap junction-coupled neurons. Apart from Cx43, the special conduction system in the ventricles contains [[Cx45]]. In the atrioventricular and [[sinoatrial node]] of mice, Cx30.2 is expressed while its orthologous protein Cx31.9 is not detectable in the human cardiac conduction system.<ref>{{cite journal|last1=Severs|first1=NJ|last2=Bruce|first2=AF|last3=Dupont|first3=E|last4=Rothery|first4=S|title=Remodelling of gap junctions and connexin expression in diseased myocardium.|journal=Cardiovascular research|date=1 October 2008|volume=80|issue=1|pages=9-19|pmid=18519446}}</ref> The most abundant Cx in the brain and heart is Cx43. In the brain, Cx43 is most prominently expressed in astrocytes but is also present in microglial cells. In the heart, Cx43 is most prominently expressed in cardiomyocytes of the ventricles, but is also present in [[atrial]] cells and [[endothelial cells]].


[[Mutation]]s in this gene have been associated with ODDD; [[Craniometaphyseal dysplasia autosomal dominant|craniometaphyseal dysplasia]]; [[sudden infant death syndrome]], which is linked to cardiac [[arrhythmia]]; [[Hallermann–Streiff syndrome]]; and heart malformations, such as [[viscero-atrial heterotaxia]].<ref name = "entrez"/><ref name = "pmid22918484"/><ref name = "pmid24434540"/><ref name="pmid14974090">{{cite journal | vauthors = Pizzuti A, Flex E, Mingarelli R, Salpietro C, Zelante L, Dallapiccola B | title = A homozygous GJA1 gene mutation causes a Hallermann-Streiff/ODDD spectrum phenotype | journal = Human Mutation | volume = 23 | issue = 3 | pages = 286 | date = Mar 2004 | pmid = 14974090 | doi = 10.1002/humu.9220 }}</ref> There have also been a few cases of reported hearing loss and skin disorders unrelated to ODDD.<ref name = "pmid24434540"/> Ultimately, GJA1 has low tolerance for deviations from its original sequence, with mutations resulting in loss- or gain-of-channel function that lead to disease phenotypes.<ref name = "pmid24434540"/> It is paradoxical, however, that patients with an array of somatic mutations in ''GJA1'' most often do not present with cardiac [[arrhythmia]]s, even though connexin-43 is the most abundant protein forming [[gap junction]]al pores in [[cardiomyocyte]]s and are essential for normal [[action potential]] propagation.<ref>{{cite journal | vauthors = Delmar M, Makita N | title = Cardiac connexins, mutations and arrhythmias | journal = Current Opinion in Cardiology | volume = 27 | issue = 3 | pages = 236–41 | date = May 2012 | pmid = 22382502 | doi = 10.1097/HCO.0b013e328352220e }}</ref>
[[Mutation]]s in this gene have been associated with ODDD; [[Craniometaphyseal dysplasia autosomal dominant|craniometaphyseal dysplasia]]; [[sudden infant death syndrome]], which is linked to cardiac [[arrhythmia]]; [[Hallermann–Streiff syndrome]]; and heart malformations, such as [[viscero-atrial heterotaxia]].<ref name = "entrez"/><ref name = "pmid22918484"/><ref name = "pmid24434540"/><ref name="pmid14974090">{{cite journal | vauthors = Pizzuti A, Flex E, Mingarelli R, Salpietro C, Zelante L, Dallapiccola B | title = A homozygous GJA1 gene mutation causes a Hallermann-Streiff/ODDD spectrum phenotype | journal = Human Mutation | volume = 23 | issue = 3 | pages = 286 | date = Mar 2004 | pmid = 14974090 | doi = 10.1002/humu.9220 }}</ref> There have also been a few cases of reported hearing loss and skin disorders unrelated to ODDD.<ref name = "pmid24434540"/> Ultimately, GJA1 has low tolerance for deviations from its original sequence, with mutations resulting in loss- or gain-of-channel function that lead to disease phenotypes.<ref name = "pmid24434540"/> It is paradoxical, however, that patients with an array of somatic mutations in ''GJA1'' most often do not present with cardiac [[arrhythmia]]s, even though connexin-43 is the most abundant protein forming [[gap junction]]al pores in [[cardiomyocyte]]s and are essential for normal [[action potential]] propagation.<ref>{{cite journal | vauthors = Delmar M, Makita N | title = Cardiac connexins, mutations and arrhythmias | journal = Current Opinion in Cardiology | volume = 27 | issue = 3 | pages = 236–41 | date = May 2012 | pmid = 22382502 | doi = 10.1097/HCO.0b013e328352220e }}</ref>

Revision as of 18:49, 21 September 2015

Template:PBB

Connexin43
connexin 43 carboxyl terminal domain
Identifiers
SymbolConnexin43
PfamPF03508
InterProIPR013124
TCDB1.A.24
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary

Gap junction alpha-1 protein (GJA1), also known as connexin 43 (Cx43), is a protein that in humans is encoded by the GJA1 gene on chromosome 6.[1][2][3] As a connexin, GJA1 is a component of gap junctions, which allow for gap junction intercellular communication (GJIC) between cells to regulate cell death, proliferation, and differentiation.[4] As a result of its function, GJA1 is implicated in many biological processes, including muscle contraction, embryonic development, inflammation, and spermatogenesis, as well as diseases, including oculodentodigital dysplasia (ODDD), heart malformations, and cancers.[3][5][6]

Structure

Connexin-43 is a 43.0 kDa protein comprised of 382 amino acids.[7] GJA1 contains a long C-terminal tail, an N-terminal domain, and multiple transmembrane domains. The protein passes through the phospholipid bilayer four times, leaving its C- and N-terminals exposed to the cytoplasm.[8] The C-terminal tail is composed of 50 amino acids and includes post-translational modification sites, as well as binding sites for transcription factors, cytoskeleton elements, and other proteins.[8][9] As a result, the C-terminal tail is central to functions such as regulating pH gating and channel assembly. Notably, the DNA region of the GJA1 gene encoding this tail is highly conserved, indicating that it is either resistant to mutations or becomes lethal when mutated. Meanwhile, the N-terminal domain is involved in channel gating and oligomerization and, thus, may control the switch between the channel’s open and closed states. The transmembrane domains form the gap junction channel while the extracellular loops facilitate proper channel docking. Moreover, two extracellular loops form disulfide bonds that interact with two hexamers to form a complete gap junction channel.[8]

The connexin-43 internal ribosome entry site is an RNA element present in the 5' UTR of the mRNA of GJA1. This internal ribosome entry site (IRES) allows cap independent translation during conditions such as heat shock and stress.[10]

Function

As a member of the connexin family, GJA1 is a component of gap junctions, which are intercellular channels that connect adjacent cells to permit the exchange of low molecular weight molecules, such as small ions and secondary messengers, to maintain homeostasis.[3][8][11]

GJA1 is the most ubiquitously expressed connexin and is detected in most cell types.[3][5][8] It is the major protein in heart gap junctions and is purported to play a crucial role in the synchronized contraction of the heart.[3] Despite its key role in the heart and other vital organs, GJA1 has a short half-life (only two to four hours), indicating that the protein undergoes daily turnover in the heart and may be highly abundant or compensated with other connexins.[8] GJA1 is also largely involved in embryonic development.[3][4] For instance, transforming growth factor-beta 1 (TGF-β1) was observed to induce GJA1 expression via the Smad and ERK1/2 signaling pathways, resulting in trophoblast cell differentiation into the placenta.[4]

Furthermore, GJA1 is expressed in many immune cells, such as eosinophils and T cells, where its gap junction function promotes the maturation and activation of these cells and, by extension, the cross-communication necessary to mount an inflammatory response.[6]

In addition, GJA1 can be found in the Leydig cells and seminiferous tubules between Sertoli cells and spermatogonia or primary spermatocytes, where it plays a key role in spermatogenesis and testis development through controlling the tight junction proteins in the blood-testis barrier.

While it is a channel protein, GJA1 can also perform channel-independent functions. In the cytoplasm, the protein regulates the microtubule network and, by extension, cell migration and polarity.[5][9] This function has been observed in brain and heart development, as well as wound-healing in endothelial cells.[9] GJA1 has also been observed to localize to the mitochondria, where it promotes cell survival by downregulating the intrinsic apoptotic pathway during conditions of oxidative stress.[11]

Clinical significance

Overall, connexins are widely distributed proteins in the body that are specifically important for functions in the heart and the brain.[12] [13][14] Six connexin subunits form a connexon or hemichannel in the plasma membrane. Interactions between two hemichannels in a head-to-head arrangement result in the formation of a gap junction channel. Hence, Gap junctions are necessary to coordinate cell function by passing electrical current flow between heart and nerve cells or by allowing exchange of chemical signals and energy substrates. In general, mutations of connexin proteins may lead to congenital diseases; the most frequent one is hearing loss. Moreover, in the heart, atrial fibrillation may result from mutations in connexin 40. However, connection proteins also play significant roles in acquired diseases. For instance, under pathological conditions, gap junctions may expand cell injury/cell death to surrounding healthy cells causing bystander effects, or "spreading" injury. Conversely, gap junctions may also act in a protective manner by supplying essential nutrients and metabolites, thereby preventing injury or death of healthy neighboring cells. Notably, in cardiac ischemia-reperfusion injury and myocardial infarction a decrease in gap junctional communications as a result of acidosis, increased calcium concentration and altered phosphorylation and nitrosylation levels. Consequently, along with other alteration in other ion channels leads to an increased risk for arrhythmia. Furthermore, in brain ischemia, astrocytic gap junctional coupling decreases, and like in the heart, closure is incomplete. Decreased coupling hampers the spatial buffering of potassium and glutamate, and limits sharing of energy substrates from the astrocytic syncytium to neurons. The remaining coupling may be sufficient to propagate bystander injury and cell death between astrocytes and between gap junction-coupled neurons. Apart from Cx43, the special conduction system in the ventricles contains Cx45. In the atrioventricular and sinoatrial node of mice, Cx30.2 is expressed while its orthologous protein Cx31.9 is not detectable in the human cardiac conduction system.[15] The most abundant Cx in the brain and heart is Cx43. In the brain, Cx43 is most prominently expressed in astrocytes but is also present in microglial cells. In the heart, Cx43 is most prominently expressed in cardiomyocytes of the ventricles, but is also present in atrial cells and endothelial cells.

Mutations in this gene have been associated with ODDD; craniometaphyseal dysplasia; sudden infant death syndrome, which is linked to cardiac arrhythmia; Hallermann–Streiff syndrome; and heart malformations, such as viscero-atrial heterotaxia.[3][5][8][16] There have also been a few cases of reported hearing loss and skin disorders unrelated to ODDD.[8] Ultimately, GJA1 has low tolerance for deviations from its original sequence, with mutations resulting in loss- or gain-of-channel function that lead to disease phenotypes.[8] It is paradoxical, however, that patients with an array of somatic mutations in GJA1 most often do not present with cardiac arrhythmias, even though connexin-43 is the most abundant protein forming gap junctional pores in cardiomyocytes and are essential for normal action potential propagation.[17]

Notably, GJA1 expression has been associated with a wide variety of cancers, including nasopharyngeal carcinoma, meningioma, hemangiopericytoma, liver tumor, colon cancer, esophageal cancer, breast cancer, mesothelioma, glioblastoma, lung cancer, adrenocortical tumors, renal cell cancer, cervical carcinoma, ovarian carcinoma, endometrial carcinoma, prostate cancer, thyroid carcinoma, and testis cancer.[5] Its role in controlling cell motility and polarity was thought to contribute to cancer development and metastasis, though its role as a gap junction protein may also be involved.[5][11] Moreover, the cytoprotective effects of this protein can promote tumor cell survival in radiotherapy treatments, while silencing its gene increases radiosensitivity. As a result, GJA1 may serve as a target for improving the success of radiotherapeutic treatment of cancer.[11] As a biomarker, GJA1 could also be used to screen young males for risk of testis cancer.[5]

Currently, only rotigaptide, an antiarrhythmic peptide-based drug, and its derivatives, such as danegaptide, have reached clinical trials for treating cardiac pathologies by enhancing GJA1 expression. Alternatively, drugs could target complementary connexins, such as Cx40, which function similarly to GJA1. However, both approaches still require a system to target the diseased tissue to avoid inducing developmental abnormalities elsewhere.[8] Thus, a more effective approach entails designing a miRNA through antisense oligonucleotides, transfection, or infection to knock down only mutant GJA1 mRNA, thus allowing the expression of wildtype GJA1 and retaining normal phenotype.[5][8]

Interactions

Gap junction protein, alpha 1 has been shown to interact with:

See also

References

  1. ^ Boyadjiev SA, Jabs EW, LaBuda M, Jamal JE, Torbergsen T, Ptácek LJ, Rogers RC, Nyberg-Hansen R, Opjordsmoen S, Zeller CB, Stine OC, Stalker HJ, Zori RT, Shapiro RE (May 1999). "Linkage analysis narrows the critical region for oculodentodigital dysplasia to chromosome 6q22-q23". Genomics. 58 (1): 34–40. doi:10.1006/geno.1999.5814. PMID 10331943.
  2. ^ Fishman GI, Eddy RL, Shows TB, Rosenthal L, Leinwand LA (May 1991). "The human connexin gene family of gap junction proteins: distinct chromosomal locations but similar structures". Genomics. 10 (1): 250–6. doi:10.1016/0888-7543(91)90507-B. PMID 1646158.
  3. ^ a b c d e f g "Entrez Gene: GJA1 gap junction protein, alpha 1, 43kDa".
  4. ^ a b c Cheng JC, Chang HM, Fang L, Sun YP, Leung PC (Jul 2015). "TGF-β1 up-regulates connexin43 expression: a potential mechanism for human trophoblast cell differentiation". Journal of Cellular Physiology. 230 (7): 1558–66. doi:10.1002/jcp.24902. PMID 25560303.
  5. ^ a b c d e f g h Chevallier D, Carette D, Segretain D, Gilleron J, Pointis G (Apr 2013). "Connexin 43 a check-point component of cell proliferation implicated in a wide range of human testis diseases". Cellular and Molecular Life Sciences. 70 (7): 1207–20. doi:10.1007/s00018-012-1121-3. PMID 22918484.
  6. ^ a b Vliagoftis H, Ebeling C, Ilarraza R, Mahmudi-Azer S, Abel M, Adamko D, Befus AD, Moqbel R (2014). "Connexin 43 expression on peripheral blood eosinophils: role of gap junctions in transendothelial migration". BioMed Research International. 2014: 803257. doi:10.1155/2014/803257. PMID 25110696.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  7. ^ "Protein sequence of human GJA1 (Uniprot ID: P17302)". Cardiac Organellar Protein Atlas Knowledgebase (COPaKB). Retrieved 18 September 2015.
  8. ^ a b c d e f g h i j k l m n Laird DW (Apr 2014). "Syndromic and non-syndromic disease-linked Cx43 mutations". FEBS Letters. 588 (8): 1339–48. doi:10.1016/j.febslet.2013.12.022. PMID 24434540.
  9. ^ a b c Kameritsch P, Pogoda K, Pohl U (Aug 2012). "Channel-independent influence of connexin 43 on cell migration". Biochimica Et Biophysica Acta. 1818 (8): 1993–2001. doi:10.1016/j.bbamem.2011.11.016. PMID 22155212.
  10. ^ Schiavi A, Hudder A, Werner R (Dec 1999). "Connexin43 mRNA contains a functional internal ribosome entry site". FEBS Letters. 464 (3): 118–22. doi:10.1016/S0014-5793(99)01699-3. PMID 10618489.
  11. ^ a b c d Ghosh S, Kumar A, Chandna S (Jul 2015). "Connexin-43 downregulation in G2/M phase enriched tumour cells causes extensive low-dose hyper-radiosensitivity (HRS) associated with mitochondrial apoptotic events". Cancer Letters. 363 (1): 46–59. doi:10.1016/j.canlet.2015.03.046. PMID 25843295.
  12. ^ Schulz, R; Görge, PM; Görbe, A; Ferdinandy, P; Lampe, PD; Leybaert, L (September 2015). "Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection". Pharmacology & therapeutics. 153: 90–106. PMID 26073311.
  13. ^ Severs, NJ; Bruce, AF; Dupont, E; Rothery, S (1 October 2008). "Remodelling of gap junctions and connexin expression in diseased myocardium". Cardiovascular research. 80 (1): 9–19. PMID 18519446.
  14. ^ Kelly, JJ; Simek, J; Laird, DW (June 2015). "Mechanisms linking connexin mutations to human diseases". Cell and tissue research. 360 (3): 701–21. PMID 25398718.
  15. ^ Severs, NJ; Bruce, AF; Dupont, E; Rothery, S (1 October 2008). "Remodelling of gap junctions and connexin expression in diseased myocardium". Cardiovascular research. 80 (1): 9–19. PMID 18519446.
  16. ^ Pizzuti A, Flex E, Mingarelli R, Salpietro C, Zelante L, Dallapiccola B (Mar 2004). "A homozygous GJA1 gene mutation causes a Hallermann-Streiff/ODDD spectrum phenotype". Human Mutation. 23 (3): 286. doi:10.1002/humu.9220. PMID 14974090.
  17. ^ Delmar M, Makita N (May 2012). "Cardiac connexins, mutations and arrhythmias". Current Opinion in Cardiology. 27 (3): 236–41. doi:10.1097/HCO.0b013e328352220e. PMID 22382502.
  18. ^ Cameron SJ, Malik S, Akaike M, Lerner-Marmarosh N, Yan C, Lee JD, Abe J, Yang J (May 2003). "Regulation of epidermal growth factor-induced connexin 43 gap junction communication by big mitogen-activated protein kinase1/ERK5 but not ERK1/2 kinase activation". The Journal of Biological Chemistry. 278 (20): 18682–8. doi:10.1074/jbc.M213283200. PMID 12637502.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  19. ^ Schubert AL, Schubert W, Spray DC, Lisanti MP (May 2002). "Connexin family members target to lipid raft domains and interact with caveolin-1". Biochemistry. 41 (18): 5754–64. doi:10.1021/bi0121656. PMID 11980479.
  20. ^ Giepmans BN, Moolenaar WH (1998). "The gap junction protein connexin43 interacts with the second PDZ domain of the zona occludens-1 protein". Current Biology. 8 (16): 931–4. doi:10.1016/S0960-9822(07)00375-2. PMID 9707407.
  21. ^ Cooper CD, Lampe PD (Nov 2002). "Casein kinase 1 regulates connexin-43 gap junction assembly". The Journal of Biological Chemistry. 277 (47): 44962–8. doi:10.1074/jbc.M209427200. PMID 12270943.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  22. ^ Giepmans BN, Feiken E, Gebbink MF, Moolenaar WH (2003). "Association of connexin43 with a receptor protein tyrosine phosphatase". Cell Communication & Adhesion. 10 (4–6): 201–5. doi:10.1080/cac.10.4-6.201.205. PMID 14681016.

Further reading

Retrieved from "https://en.wikipedia.org/w/index.php?title=GJA1&oldid=682130295"